Mucous Membrane Pemphigoid (MMP)

Overview

Mucous Membrane Pemphigoid (MMP), also known as cicatricial pemphigoid, is a rare, chronic, autoimmune blistering disease that primarily targets the moist (mucosal) surfaces of the body. Unlike the more common skin‑limited bullous pemphigoid, MMP predominantly affects the lining of the mouth, eyes, nose, throat, genital tract, and sometimes the esophagus.

• Who it affects: Adults, with a median onset age of 55‑65 years. Women are slightly more often affected than men (approximately 1.2 : 1).
• Prevalence: Estimated at 1–2 cases per 1 million people worldwide; however, exact numbers vary because the disease is often under‑diagnosed.¹
• Geography: No strong ethnic or geographic predilection, though most published data come from North America and Europe.

MMP is characterized by the formation of fragile blisters that quickly rupture, leaving behind painful erosions and, over time, scar tissue that can cause functional impairment—especially when the eyes are involved.

Symptoms

Because MMP can involve any mucosal surface, symptoms differ according to the site of disease. Below is a comprehensive list.

Oral (most common site)

• Blisters that rupture within hours, leaving painful erosions.
• White‑lacy (Wickham’s striae) or erythematous patches.
• Difficulty eating, drinking, or speaking.
• Bleeding gums or persistent soreness.

Ocular (second most frequent serious site)

• Redness, burning, or gritty sensation.
• Conjunctival scarring (symblepharon) leading to eyelid adhesion.
• Decreased vision, photophobia, or even blindness if untreated.

Nasal & Sinus

• Crusting, ulceration, or blockage of the nostrils.
• Recurrent sinus infections.

Pharyngeal & Laryngeal

• Sore throat, dysphagia (difficulty swallowing).
• Hoarseness or voice changes.
• Airway obstruction in severe cases.

Genital & Anorectal

• Vulvar or penile erosions, itching, or burning.
• Rectal ulcerations causing pain with bowel movements.

Esophageal

• Odynophagia (painful swallowing) and strictures.
• Weight loss from reduced oral intake.

Skin (rare)

• Few tense bullae on trauma‑prone areas; usually not the primary presentation.

Causes and Risk Factors

MMP is an autoimmune condition—your immune system mistakenly attacks components of the basement membrane (the thin layer that anchors mucosal epithelium to underlying tissue).

Underlying Immunologic Mechanisms

• Auto‑antibodies (IgG and sometimes IgA) target proteins such as BP180 (type XVII collagen), laminin‑332, and α6β4 integrin.²
• Binding triggers complement activation and recruitment of neutrophils and eosinophils, leading to tissue damage and blister formation.

Identified Risk Factors

• Age: Incidence rises after age 50.
• Sex: Slight female predominance.
• Genetics: Certain HLA alleles (e.g., HLA‑DR4) may increase susceptibility, though data are limited.
• Medications: Rarely, drugs that modify immunity (e.g., checkpoint inhibitors) have been reported to trigger MMP‑like reactions.
• Other autoimmune diseases: Association with rheumatoid arthritis, thyroid disease, and vitiligo in a minority of patients.

Diagnosis

Because early lesions mimic other ulcerative conditions (candidiasis, erosive lichen planus, pemphigus vulgaris), a systematic approach is essential.

Clinical Evaluation

• Detailed history of symptom onset, distribution, and scarring.
• Thorough oral and ophthalmologic examination; referral to an eye specialist is often required.

Biopsy & Histopathology

Two biopsies are recommended:

1. Lesional biopsy: Shows subepithelial (subepidermal) cleft with predominantly eosinophils and neutrophils.
2. Perilesional (non‑blistered) biopsy: Used for direct immunofluorescence (DIF).

Direct Immunofluorescence (DIF)

Gold standard. The perilesional sample reveals linear deposition of IgG and/or complement component C3 along the basement membrane zone.

Indirect Immunofluorescence (IIF) & ELISA

• IIF on salt‑split skin can differentiate MMP from bullous pemphigoid.
• ELISA tests for BP180 and laminin‑332 antibodies aid in confirming the diagnosis and may correlate with disease severity.

Additional Tests

• Complete blood count, liver/kidney panels to establish baseline before systemic therapy.
• Serology for infectious triggers (HSV, HIV) if clinical suspicion exists.
• Ophthalmic imaging (slit‑lamp) to document conjunctival scarring.

Treatment Options

Management aims to control inflammation, prevent scarring, and preserve function. Therapy is individualized based on disease extent and organ involvement.

Topical Therapies (for localized disease)

• High‑potency corticosteroids: Clobetasol propionate 0.05% gel or ointment applied to oral lesions 2–3 times daily.
• Topical calcineurin inhibitors: Tacrolimus 0.1% or pimecrolimus 1% swish‑and‑spit for oral mucosa; useful when steroids are contraindicated.

Systemic Medications (moderate to severe disease)

1. Corticosteroids: Prednisone 0.5–1 mg/kg/day for induction; taper as quickly as feasible.
2. Immunosuppressive agents:
   • Azathioprine 2–3 mg/kg/day
   • Mycophenolate mofetil 2–3 g/day divided BID
   • Methotrexate 10–25 mg weekly (if no liver disease)
3. Biologic therapy (refractory cases):
   • Rituximab (anti‑CD20) – 1 g IV on days 1 and 15, then maintenance dosing.
   • Dupilumab (IL‑4Rα blocker) – emerging data show benefit for ocular MMP.³

Adjunctive Therapies

• Intravenous immunoglobulin (IVIG): 2 g/kg divided over 2–5 days for severe, steroid‑resistant disease.
• Plasmapheresis: Considered in life‑threatening airway involvement.

Procedural Interventions

• Ophthalmic surgery: Amniotic membrane transplantation or fornix reconstruction for advanced conjunctival scarring.
• Endoscopic dilation: For esophageal strictures causing dysphagia.

Lifestyle & Supportive Measures

• Gentle oral hygiene – use soft‑bristled toothbrushes, alcohol‑free mouthwashes, and avoid spicy/acidic foods.
• Artificial tears or lubricating eye ointments for ocular dryness.
• Smoking cessation – smoking worsens oral and ocular healing.

Living with Mucous Membrane Pemphigoid

Chronic diseases require daily strategies to maintain quality of life.

Oral Care

• Brush after each meal with a soft brush; consider a silicone brush for delicate mucosa.
• Rinse with saline or non‑alcoholic, sugar‑free mouthwash (e.g., chlorhexidine 0.12% once daily).
• Stay hydrated; sip water frequently to keep mucosa moist.

Eye Care

• Apply preservative‑free artificial tears 4–6 times daily.
• Use a warm compress and lid hygiene to reduce crusting.
• Attend regular ophthalmology appointments—at least every 3–6 months for active disease.

Nutrition

• Choose soft, bland foods (e.g., oatmeal, smoothies, mashed potatoes).
• Avoid citrus, tomato products, nuts, and crunchy items that can traumatize lesions.
• Consider a nutritionist consult if weight loss exceeds 5 % of body weight.

Psychosocial Support

• Join support groups (e.g., Rare Autoimmune Disease Alliance) to share experiences.
• Mind‑body techniques—meditation, gentle yoga—can reduce stress, which may lessen flare‑ups.
• Seek counseling if chronic pain or visual changes affect mental health.

Medication Management

• Keep an up‑to‑date medication list; discuss any new drugs with your dermatologist or rheumatologist.
• Monitor labs (CBC, LFTs, renal function) as recommended for systemic agents.
• Never abruptly stop steroids; taper under physician guidance to avoid adrenal insufficiency.

Prevention

Because MMP is autoimmune, true primary prevention is not possible. However, steps can reduce triggers and limit disease progression.

• Avoid oral trauma: Gentle brushing, no flossing over active lesions, and use of a soft diet during flares.
• Protect eyes: Wear sunglasses outdoors and avoid exposure to dust or chemicals.
• Infection control: Treat oral candidiasis promptly; it can mimic or aggravate MMP lesions.
• Medication vigilance: Discuss any new prescription or over‑the‑counter medications with your specialist, especially drugs known to affect immunity.
• Regular follow‑up: Early detection of new mucosal involvement prevents irreversible scarring.

Complications

If left untreated or poorly controlled, MMP can lead to serious, sometimes irreversible damage.

• Ocular blindness: Progressive conjunctival scarring (symblepharon, ankyloblepharon).
• Airway obstruction: Laryngeal or pharyngeal strictures, especially in severe cases.
• Esophageal stricture: Dysphagia and weight loss.
• Permanent oral scarring: Limits mouth opening (microstomia) and interferes with nutrition.
• Secondary infections: Chronic ulcerations predispose to bacterial or fungal superinfection.
• Medication side effects: Long‑term steroids → osteoporosis, diabetes; immunosuppressants → increased infection risk.

When to Seek Emergency Care

---

**Sources**

1. Joly P, et al. “Mucous membrane pemphigoid: diagnostic and therapeutic challenges.” *J Am Acad Dermatol.* 2015;73(6):1085‑1095. PMCID: PMC5177694
2. Kirtschig G, et al. “Autoantibodies in mucous membrane pemphigoid.” *Clin Exp Dermatol.* 2013;38(8):736‑747. PMCID: PMC3629602
3. Cleveland Clinic. “Rituximab for autoimmune blistering diseases.” 2022. clevelandclinic.org
4. Mayo Clinic. “Mucous membrane pemphigoid (cicatricial pemphigoid).” Updated 2023. mayoclinic.org
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Pemphigoid diseases.” 2022. niams.nih.gov